NO742027L - - Google Patents
Info
- Publication number
- NO742027L NO742027L NO742027A NO742027A NO742027L NO 742027 L NO742027 L NO 742027L NO 742027 A NO742027 A NO 742027A NO 742027 A NO742027 A NO 742027A NO 742027 L NO742027 L NO 742027L
- Authority
- NO
- Norway
- Prior art keywords
- calcium
- calcium carbonate
- chlorophenoxyisobutyrate
- water
- monohydrate
- Prior art date
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 50
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 25
- 239000011575 calcium Substances 0.000 claims description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 8
- 229960001214 clofibrate Drugs 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 alkaline earth metal salts Chemical class 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Chemical class CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 150000001444 androsterones Chemical class 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940042208 calcium carbonate oral suspension Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107170 cholestyramine resin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960001767 dextrothyroxine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Chemical class OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical class OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/370,506 US3952096A (en) | 1973-06-15 | 1973-06-15 | Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO742027L true NO742027L (fr) | 1975-01-13 |
Family
ID=23459961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO742027A NO742027L (fr) | 1973-06-15 | 1974-06-05 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3952096A (fr) |
| JP (1) | JPS5031018A (fr) |
| BE (1) | BE815143A (fr) |
| CA (1) | CA1038402A (fr) |
| CH (1) | CH594588A5 (fr) |
| DE (1) | DE2428639A1 (fr) |
| DK (1) | DK316374A (fr) |
| FI (1) | FI178174A (fr) |
| FR (1) | FR2233043B1 (fr) |
| GB (1) | GB1469457A (fr) |
| IE (1) | IE39276B1 (fr) |
| IL (1) | IL45014A (fr) |
| NL (1) | NL7407847A (fr) |
| NO (1) | NO742027L (fr) |
| PH (1) | PH13350A (fr) |
| SE (1) | SE7407561L (fr) |
| ZA (1) | ZA743124B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1573487A (en) * | 1977-05-23 | 1980-08-28 | Bristol Myers Co | Bile acid binding composition |
| FR2428629A1 (fr) * | 1978-06-14 | 1980-01-11 | Hexachimie | Nouveaux composes bis(aryloxycarboxyliques), leur preparation et leur utilisation en therapeutique |
| US4591500A (en) * | 1983-04-25 | 1986-05-27 | Microencapsulation S.A. | Tablet having the shape of a capsule, process and device for its preparation |
| US4824672A (en) * | 1986-06-06 | 1989-04-25 | Hauser-Kuhrts, Inc. | Method and composition for reducing serum cholesterol |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| WO2006058199A1 (fr) * | 2004-11-23 | 2006-06-01 | Fazix Corporation | Procedes de modulation de niveaux de cholesterol a lipoproteines de haute densite et formulations pharmaceutiques a cet effet |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB860303A (en) * | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
| CH515207A (de) * | 1966-06-27 | 1971-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen Bis-(p-Chlorphenoxy)-essigsäureestern |
-
1973
- 1973-06-15 US US05/370,506 patent/US3952096A/en not_active Expired - Lifetime
-
1974
- 1974-05-15 CA CA199,940A patent/CA1038402A/fr not_active Expired
- 1974-05-16 ZA ZA00743124A patent/ZA743124B/xx unknown
- 1974-05-16 BE BE144412A patent/BE815143A/fr unknown
- 1974-05-21 JP JP49056207A patent/JPS5031018A/ja active Pending
- 1974-05-21 IE IE1081/74A patent/IE39276B1/xx unknown
- 1974-05-31 GB GB2418374A patent/GB1469457A/en not_active Expired
- 1974-06-05 NO NO742027A patent/NO742027L/no unknown
- 1974-06-07 SE SE7407561A patent/SE7407561L/ not_active Application Discontinuation
- 1974-06-07 FR FR7419683A patent/FR2233043B1/fr not_active Expired
- 1974-06-11 FI FI1781/74A patent/FI178174A/fi unknown
- 1974-06-12 NL NL7407847A patent/NL7407847A/xx not_active Application Discontinuation
- 1974-06-12 IL IL45014A patent/IL45014A/xx unknown
- 1974-06-13 PH PH15933A patent/PH13350A/en unknown
- 1974-06-13 DK DK316374A patent/DK316374A/da unknown
- 1974-06-14 CH CH818674A patent/CH594588A5/xx not_active IP Right Cessation
- 1974-06-14 DE DE2428639A patent/DE2428639A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL45014A0 (en) | 1974-09-10 |
| DK316374A (fr) | 1975-02-10 |
| DE2428639A1 (de) | 1975-01-09 |
| IE39276L (en) | 1974-12-15 |
| FR2233043B1 (fr) | 1978-07-21 |
| FR2233043A1 (fr) | 1975-01-10 |
| IL45014A (en) | 1978-01-31 |
| ZA743124B (en) | 1975-05-28 |
| JPS5031018A (fr) | 1975-03-27 |
| IE39276B1 (en) | 1978-09-13 |
| US3952096A (en) | 1976-04-20 |
| AU6992074A (en) | 1975-12-11 |
| FI178174A (fr) | 1974-12-16 |
| PH13350A (en) | 1980-03-20 |
| BE815143A (fr) | 1974-11-18 |
| SE7407561L (fr) | 1974-12-16 |
| CH594588A5 (fr) | 1978-01-13 |
| GB1469457A (en) | 1977-04-06 |
| NL7407847A (fr) | 1974-12-17 |
| CA1038402A (fr) | 1978-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4859704A (en) | Water soluble ibuprofen compositions and methods of making them | |
| NO742027L (fr) | ||
| JPH09255570A (ja) | 血中脂質濃度を低減させる薬剤及び可食性組成物 | |
| JPS6322520A (ja) | 学習促進・記憶増強用薬剤 | |
| US20130150448A1 (en) | Dimeric double metal salts of (-) hydroxycitric acid, methods of making and uses of same | |
| CN100475804C (zh) | 一类异色满酮-4衍生物、其制备方法及其医疗用途 | |
| US20240197665A1 (en) | Pharmaceutical Composition For Treating Hyperlipidemia And Preparation Method Therefor | |
| CN101715448A (zh) | 一种咪唑-5-羧酸衍生物的治疗用途 | |
| WO1998000148A1 (fr) | Preparations medicamenteuses contenant de la creatine et au moins un sel de calcium, de magnesium, de manganese ou de zinc | |
| DE1543733C3 (de) | Aluminium-bis-alpha-(p-chlorphenoxy) isobutyrat und diese Verbindung als Wirkstoff enthaltende Hellmittel | |
| DE2038836C3 (de) | Arzneimittel | |
| EP0308665B1 (fr) | Sels de l'acide 5-aminosalicylique et préparations pharmaceutiques qui les contiennent | |
| DE2408372C3 (de) | Therapeutisch verträgliche Salze der p-Chlorhippursäure und diese oder p-Chlorhippursäure enthaltende pharmazeutische Zubereitungen | |
| US4055648A (en) | Papaverine thienyl-carboxylates and medicaments containing them | |
| US3963834A (en) | Pharmaceutical compositions for the treatment of hydropic conditions | |
| JP3279695B2 (ja) | 分岐ガラクトオリゴ糖を有効成分とするミネラル吸収促進剤 | |
| JPS63198630A (ja) | 脂質代謝改善剤 | |
| CN111732524B (zh) | 一种酰基胍类化合物及其制备方法与应用 | |
| JP2001517227A (ja) | Ｌ−カルニチンもしくはアルカノイル−ｌ−カルニチンと２−アミノエタンスルホン酸との非吸湿性塩を含有する経口投与に適した固体状組成物 | |
| EP1007522B1 (fr) | 2- 4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]piperazin-1-yl -5-fluoropyrimidine, sa preparation et son utilisation therapeutique | |
| WO2005115404A1 (fr) | Combinaison de sels de l'acide o-acetylsalicylique et d'inhibiteurs d'alpha-glucosidase | |
| US4215143A (en) | Anti-ulcer pharmaceutical composition containing inositol hexasulfate aluminum or sodium aluminum salt as active ingredient | |
| RU2203656C1 (ru) | Фармацевтическая композиция с антидиабетическим действием на основе производного оксованадия и способ его получения | |
| JPS63258421A (ja) | 糖ラクタムを含有する抗炎症剤 | |
| EP0317105A2 (fr) | Dérivé de phénylalanine et ses utilisations |